Roxadustat

Research use only, not for human use.

Roxadustat (FG4592, FG-4592) is a potent, orally available HIF prolyl hydroxylase (HIF-PHD) with IC50 of 591.4 nM.

Roxadustat (FG4592, FG-4592) is a potent, orally available HIF prolyl hydroxylase (HIF-PHD) with IC50 of 591.4 nM; FG-4592 stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, demonstrates potential for treatment of anemia.Anemia Phase 3 Clinical(In Vitro):Roxadustat (5-50 μM; 6 hours) significantly inhibits TBHP-induced apoptosis in PC12 cells.Roxadustat (50 μM; 6 hours) stabilizes HIF-1α protein expression in PC12 cells.(In Vivo):Roxadustat (50 mg/kg; i.p.; daily for 7 days) protects the survival of motor neurons and improves recovery from spinal cord injury.

Roxadustat (5-50 μM; 6 hours) significantly inhibits TBHP-induced apoptosis in PC12 cells.Roxadustat (50 μM; 6 hours) stabilizes HIF-1α protein expression in PC12 cells.Apoptosis Analysis Cell Line:PC12 cells Concentration:5, 20, 50 μM Incubation Time:6 hours Result:Significantly inhibited TBHP-induced apoptosis.Western Blot Analysis Cell Line:PC12 cells Concentration:50 μM Incubation Time:6 hours Result:stabilized HIF-1α protein expression.

Roxadustat (50 mg/kg; i.p.; daily for 7 days) protects the survival of motor neurons and improves recovery from spinal cord injury. Animal Model:12-week female C57BL/6 mice Dosage:50 mg/kg Administration: Intraperitoneal injection; daily for 7 days Result:Protected the survival of motor neurons and improved recovery from spinal cord injury.

FG4592 | FG-4592

Angiogenesis

HIF/HIF Prolyl-hydroxylase

HIF-PH

Other Indications

Anemia

808118-40-3

352.3407

C19H16N2O5

>98% (HPLC)

DMSO: ≥ 46 mg/mL

O=C(O)CNC(C1=C(O)C2=C(C(C)=N1)C=C(OC3=CC=CC=C3)C=C2)=O

Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-

(-20℃)

With Ice Pack

≥ 2 years